SecBot SecBot
DEFA14A ·Filed Jun 5, 2026

CDNA

CareDx, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001104659-26-070996
Proxy solicitation materials
Actionable Insight • Neutral

Routine proxy supplement with no new financial information. Monitor the June 11 annual meeting for say-on-pay vote outcome, but no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$21.95
T+0 close · Jun 5, 2026 · via day close
Latest settled
+32.39%
T+20 · $29.06
Vs SPY
+30.76%
α at T+20
Next horizon
T+60
due 3mo ago
  1. T+0 · Jun 8 $21.95entry
  2. T+1 · 5mo ago +3.64%α +3.94% · $22.75
  3. T+5 · 5mo ago +9.70%α +7.59% · $24.08
  4. T+20 · 4mo ago +32.39%α +30.76% · $29.06
  5. T+60 · due 3mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CareDx filed a DEFA14A supplementing its 2026 proxy statement to clarify the calculation of the 2025 cash bonus program metrics. The supplement provides as-adjusted figures for Adjusted EBITDA ($38.5M, 123% of target) and Cash ($288M, 200% of target), but does not change any previously disclosed bonus payouts or voting matters. This is a routine clarification with no material financial impact.

Key Financial Metrics

Vote
say on pay
Meeting
2026-06-11

Key Facts

  • Supplement clarifies 2025 cash bonus program metrics: Revenue $380M (88% of target), Adjusted EBITDA $38.5M (123% of target), Cash $288M (200% of target).
  • Total financial goals achieved at 124% of target.
  • No changes to previously disclosed bonus payouts or voting proposals.
  • Annual meeting scheduled for June 11, 2026.

Financial Impact

No change to previously disclosed bonus amounts; total achievement 124% of target.

revenueadjusted EBITDAcash

Risk Factors

  • None from this filing; routine disclosure.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
62% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001104659-26-070996
Document: 0001104659-26-070996-index-headers.html0001104659-26-070996
Document: 0001104659-26-070996-index.html0001104659-26-070996
Document: 0001104659-26-070996.txt0001104659-26-070996

US Market Status

Market Closed · Opens Wed (9h 53m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 5, 2026